Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q4 2025
Aurinia Pharmaceuticals (AUPH) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Aurinia Pharmaceuticals (AUPH) reported revenue of $77.1M for the fourth quarter 2025 (Q4 2025), +29% from a year earlier and +5% from the quarter before. Operating margin was 43.1%, net earnings $211M (273.4% of revenue).
Aurinia Pharmaceuticals, Q4 2025: revenue $77.1M (+29% year over year), operating margin 43.1%, net earnings $211M, operating cash flow $45.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $77.1M | +5% | +29% |
| Operating profit | $33.2M | +12% | — |
| Net earnings | $211M | +568% | 148× |
| Operating cash flow | $45.7M | +3% | +52% |
What changed
Revenue was $77.1M in Q4 2025, up 29% year over year and up 5% from the previous quarter. Net product sales was the largest line at 96% of revenue.
Operating profit was $33.2M, a 43.1% margin (up 45.9 points year over year). Total costs fell 29% while revenue rose 29%. Net earnings were $210.8M, up 14651% year over year. The tax line was a benefit of $175.1M on pre-tax earnings of $35.7M.
Operating cash flow was $45.7M (up 52% year over year), 22% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $6.7M of share-based compensation. Working capital and other items used $176.7M.
Questions
What was Aurinia Pharmaceuticals' revenue in the fourth quarter 2025?
Aurinia Pharmaceuticals (AUPH) reported revenue of $77.1M for the fourth quarter 2025 (Q4 2025), +29% from a year earlier and +5% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $33.2M (43.1% of revenue) and net earnings $211M.